Ovid Therapeutics (NASDAQ: OVID) net income
Ovid Therapeutics reported a net loss of $17.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $26.4m.
Ovid Therapeutics's best year of the last 10 was fiscal 2021. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$17.4m | — | −240.1% | — |
| 2024 | −$26.4m | — | −4,670.1% | — |
| 2023 | −$52.3m | — | −13,351.8% | −$0.74 |
| 2022 | −$54.2m | −144.1% | −3,604.7% | −$0.77 |
| 2021 | $122.8m | — | 58.9% | $1.78 |
| 2020 | −$81.0m | — | −642.3% | −$1.39 |
| 2019 | −$60.5m | — | — | — |
| 2018 | −$52.0m | — | — | — |
| 2017 | −$64.8m | — | — | — |
| 2016 | −$22.4m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Ovid Therapeutics net income compared with its sector
By net income for its latest fiscal year, Ovid Therapeutics ranks 204th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Ovid Therapeutics, −240.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 202nd | Alpha Teknova | −$17.3m | −42.6% |
| 203rd | CytomX Therapeutics | −$17.4m | −22.8% |
| 204th | Ovid Therapeutics | −$17.4m | −240.1% |
| 205th | RadNet | −$18.7m | −0.9% |
| 206th | SI-Bone | −$18.9m | −9.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Ovid Therapeutics
- How much did Ovid Therapeutics earn in fiscal 2025?
- Ovid Therapeutics reported a net loss of $17.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $26.4m.
- What was the most profitable year for Ovid Therapeutics?
- Of its last 10 fiscal years, fiscal 2021, with $122.8m.
- Where does Ovid Therapeutics rank in its sector by net income?
- It ranks 204th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Ovid Therapeutics come from?
- From the annual report (Form 10-K) that Ovid Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Ovid Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Ovid Therapeutics: the Ovid Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.